Brought to you by 
ProMetic, NantPharma create NantPro to develop plasma-derived biopharma product
14 Jan 2021
Executive Summary
ProMetic Life Sciences Inc. (therapeutics for cancer and hematology) and NantPharma LLC (NantWorks LLC’s one-year-old division focused on biologically derived oncology and critical care injectables) have created an affiliate company, NantPro BioSciences LLC, to develop and commercialize in the US a plasma-derived biopharmaceutical for autoimmune disease and other conditions.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ProMetic, NantPharma create NantPro to develop plasma-derived biopharma product
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice